Nektar, Cellular Biomedicine Enter New Clinical Study Collaboration
(RTTNews) - Nektar Therapeutics (NKTR) announced Wednesday that it has entered into a new clinical study collaboration with Cellular Biomedicine Group Inc. (CBMG).
The study will evaluate Nektar's NKTR-255, a novel interleukin-15 (IL-15) receptor agonist, in combination with CBMG's C-TIL051, a tumor-infiltrating lymphocyte (TIL) therapy, in advanced non-small cell lung cancer (NSCLC) patients that are relapsed or refractory to anti-PD-1 therapy.
Preclinical and early clinical data suggest that IL-15 can improve proliferation and persistence of cellular therapies including TIL, TCR, and CAR-T therapies to increase specific anti-tumor activity.
Under the new collaboration, CBMG will add NKTR-255 to its ongoing CBMG-sponsored Phase 1 clinical trial evaluating C-TIL051 in NSCLC patients who have relapsed on or were refractory to anti-PD-1 therapy.
The study is expected to enroll a total of 20 patients. Nektar will contribute NKTR-255 supply for the study. Nektar and CBMG will each maintain existing global rights to their respective investigational medicines.
For More Such Health News, visit rttnews.com
Nektar Therapeutics Promotes Chief Accounting Officer Jillian Thomsen To CFO
U.S. GDP Jumps More Than Previously Estimated In Q2
U.S. Weekly Jobless Claims Edge Down To 229,000
FTSE 100 Down 0.4% In Cautious Trade
CAC Up Slightly; Pernod Ricard Rises On Earnings
DAX Retreats After Firm Start, Down Marginally
Swiss Franc Rises Against Majors
